The biotechnology company Securecell AG from Urdorf in the canton of Zurich is part of a British-Swiss project aiming to develop solutions for the automation of bioprocesses and digitalization in the area of cell and gene research, further details of which can be found in a press release. Innovate UK (iUK), the United Kingdom’s national innovation agency, and Innosuisse, the Swiss Innovation Agency, are jointly establishing a project to promote innovation in relation to the development of cell and gene therapies (CGT), as the press release explains further. In addition to Securecell, the project consortium also includes Cell and Gene Therapy Catapult Limited in London and DataHow from Zurich.
The project will support cutting-edge research and the development of life-saving therapeutics, with the aim of accelerating their market launch. The collaboration also serves to systematically integrate a range of advanced process analytical technologies (PATs) into a gene therapy manufacturing process.
By seamlessly integrating Securecell’s automated sampling platform Numera and process management system Lucullus, these PATs will be available inline or online and will facilitate the provision of real-time data for advanced process control.
All of the generated bioprocess and analytical data will be immediately transferred from Lucullus to DataHowLab, the innovative hybrid modeling software developed by DataHow. This software solution facilitates computational process development, in addition to enabling scale-ups and real-time predictions of future process conditions, as Securecell explains in the press release. ce/gba
Related news
Meet with an expansion expert
Our services are free of charge and include:
- Introduction to key contacts in industry, academia, and government
- Advice on regulatory framework, taxes, labor, market, and setting up a company
- Custom-made fact-finding visits, including office and co-working space